Joan Bladé

1.7k total citations
13 papers, 267 citations indexed

About

Joan Bladé is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Joan Bladé has authored 13 papers receiving a total of 267 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Hematology, 9 papers in Oncology and 7 papers in Molecular Biology. Recurrent topics in Joan Bladé's work include Multiple Myeloma Research and Treatments (12 papers), Cancer Treatment and Pharmacology (6 papers) and Protein Degradation and Inhibitors (5 papers). Joan Bladé is often cited by papers focused on Multiple Myeloma Research and Treatments (12 papers), Cancer Treatment and Pharmacology (6 papers) and Protein Degradation and Inhibitors (5 papers). Joan Bladé collaborates with scholars based in Spain, United States and Italy. Joan Bladé's co-authors include Jesús F. San Miguel, Joaquı́n Dı́az-Mediavilla, Marı́a Jesús Moro, Júlia Almeida, Alberto Órfão, Javier Fernández‐Calvo, C López-Berges, Dolores Caballero, José‐Ángel Hernández‐Rivas and Gema Mateo and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Haematology.

In The Last Decade

Joan Bladé

11 papers receiving 261 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joan Bladé Spain	7	242	172	113	79	13	13	267
Wolney Barreto Brazil	6	155 0.6×	125 0.7×	106 0.9×	47 0.6×	30 2.3×	10	194
Diane E. Durecki United States	6	320 1.3×	320 1.9×	170 1.5×	42 0.5×	16 1.2×	8	374
Pamela Hardwick United States	6	286 1.2×	227 1.3×	183 1.6×	34 0.4×	12 0.9×	13	305
Laura Rosiñol Spain	5	152 0.6×	94 0.5×	89 0.8×	29 0.4×	8 0.6×	18	159
Agne Paner United States	9	160 0.7×	217 1.3×	114 1.0×	31 0.4×	18 1.4×	33	282
Sara Bringhen Italy	3	376 1.6×	310 1.8×	224 2.0×	35 0.4×	15 1.2×	4	397
Cecilia Rus Italy	5	361 1.5×	248 1.4×	203 1.8×	34 0.4×	13 1.0×	12	378
Dixil Francis United States	4	231 1.0×	197 1.1×	100 0.9×	32 0.4×	18 1.4×	5	279
Laure Buisson France	4	176 0.7×	142 0.8×	64 0.6×	19 0.2×	16 1.2×	5	191
Cinnie Yentia Soekojo Singapore	10	176 0.7×	202 1.2×	110 1.0×	28 0.4×	21 1.6×	30	298

Countries citing papers authored by Joan Bladé

Since Specialization

Citations

This map shows the geographic impact of Joan Bladé's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joan Bladé with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joan Bladé more than expected).

Fields of papers citing papers by Joan Bladé

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joan Bladé. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joan Bladé. The network helps show where Joan Bladé may publish in the future.

Co-authorship network of co-authors of Joan Bladé

This figure shows the co-authorship network connecting the top 25 collaborators of Joan Bladé. A scholar is included among the top collaborators of Joan Bladé based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joan Bladé. Joan Bladé is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Gay, Francesca, Wilfried Roeloffzen, Meletios Α. Dimopoulos, et al.. (2025). Sustained MRD negativity in patients with newly diagnosed multiple myeloma treated with carfilzomib-lenalidomide-dexamethasone with or without isatuximab (phase III IsKia trial).. Journal of Clinical Oncology. 43(16_suppl). 7502–7502.

Ramón, Cristina De, Elizabeta A. Rojas, Irena Misiewicz-Krzemińska, et al.. (2024). Expression profile of Bcl‐2 family proteins in newly diagnosed multiple myeloma patients. HemaSphere. 8(12). e70036–e70036.

Granell, Miquel, Xavier Calvo, Antoni García‐Guiñón, et al.. (2017). Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition. Haematologica. 102(6). 1099–1104. 75 indexed citations

Larrea, Carlos Fernández de, et al.. (2016). Efficacy of Novel Agents on Soft-Tissue Plasmacytomas in Patients with Relapsed Multiple Myeloma. Blood. 128(22). 5709–5709. 1 indexed citations

Lonial, Sagar, Brendan M. Weiss, Saad Z. Usmani, et al.. (2015). Phase II study of daratumumab (DARA) monotherapy in patients with ≥ 3 lines of prior therapy or double refractory multiple myeloma (MM): 54767414MMY2002 (Sirius).. Journal of Clinical Oncology. 33(15_suppl). LBA8512–LBA8512. 7 indexed citations

Larrea, Carlos Fernández de, María Teresa Cibeira, Laura Rosiñol, et al.. (2014). Smoldering Multiple Myeloma: Impact of the Evolving Pattern on Early Progression. Blood. 124(21). 3363–3363. 7 indexed citations

Mateos, María‐Victoria, Albert Oriol, Ana-Isabel Teruel, et al.. (2011). Maintenance Therapy with Bortezomib Plus Thalidomide (VT) or Bortezomib Plus Prednisone (VP) In Elderly Myeloma Patients Included In the GEM2005MAS65 Spanish Randomized Trial. Blood. 118(21). 477–477. 5 indexed citations

Larrea, Carlos Fernández de, Laura Rosiñol, María Teresa Cibeira, et al.. (2010). Extensive soft-tissue involvement by plasmablastic myeloma arising from displaced humeral fractures. European Journal Of Haematology. no–no. 1 indexed citations

Bladé, Joan, Ma Teresa Cibeira, Laura Rosiñol, & Carlos Fernández de Larrea. (2009). Extramedullary Myeloma.. Blood. 114(22). SCI–5. 1 indexed citations

10.

Miguel, Jesús F. San, Orhan Sezer, David S. Siegel, et al.. (2009). A Phase IB, Multi-Center, Open-Label Dose-Escalation Study of Oral Panobinostat (LBH589) and I.V. Bortezomib in Patients with Relapsed Multiple Myeloma.. Blood. 114(22). 3852–3852. 11 indexed citations

11.

Miguel, Jesús F. San, Júlia Almeida, Gema Mateo, et al.. (2002). Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome. Blood. 99(5). 1853–1856. 99 indexed citations

12.

Bladé, Joan. (2001). Thalidomide in refractory and relapsing multiple myeloma. Seminars in Oncology. 28(6). 588–592. 28 indexed citations

13.

Bladé, Joan, C Rozmán, Francisco Cervantes, Joan Carles Reverter, & Emili Montserrat. (1989). A new prognostic system for multiple myeloma based on easily available parameters. British Journal of Haematology. 72(4). 507–511. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact